Piper Sandler analyst Yasmeen Rahimi downgraded Tvardi Therapeutics (TVRD) to Neutral from Overweight with a price target of $4, down from $78. The firm, which had expectations for clean safety and tolerability and some separation in FVC based on the previously “encouraging” blinded preliminary data is “disappointed” to see TVRD report TTI-101 showed no benefit in preliminary data from the 12-week Phase 2 REVERT-IPF study. Given TTI-101’s Phase 2 REVERT-IPF failure, the firm removed this asset from its model and notes that its revised price target is based on Tvardi’s $4 in cash per share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVRD:
- Morning Movers: Bloom Energy surges following $5B investment from Brookfield
- Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?
- Tvardi says benefit of TTI-101 treatment not observed in REVERT trial
- Tvardi Therapeutics initiated with an Overweight at Barclays
- BTIG biotech analyst holds a dinner meeting